UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, I ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2020 Earnings Conference Call May 6, 2020 5:00 PM ET Company Participants Ron Hutton - Vice President and Treasurer Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President and Chief Financial Officer Andy Last - Executive Vice President and Chief Operating Officer Annette Tumolo - President of Life Science Group Dara Wright - President of the Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Patrick Donnell ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its ch ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2019 Earnings Conference Call February 13, 2020 5:00 PM ET Company Participants Ron Hutton - Vice President & Treasurer Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President & Chief Financial Officer Andy Last - Executive Vice President & Chief Operating Officer Annette Tumolo - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Dan Leonard - Wells Far ...

BIO RAD Bio-Rad Laboratories, Inc. J.P. Morgan 2020 Healthcare Conference Forward-Looking Statements Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our performance in high growth emerging markets, continuing innovation and new products and technologies, our new focus on lab to clinic solutions, continuing and emerging leadership positions in various markets, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIE ...

Bio Rad Laboratories, Inc. (NYSE:BIO) Q3 2019 Earnings Conference Call October 31, 2019 5:00 PM ET Company Participants Ronald Hutton - VP & Treasurer Ilan Daskal - EVP & CFO Norman Schwartz - Chairman, CEO & President Andrew Last - EVP & COO Annette Tumolo - EVP & President, Life Science Group John Hertia - EVP & President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Jack Meehan - Barclays Bank Operator Ladies and gentlemen, thank you for standing by, and welcome t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, IN ...

Bio Rad Laboratories (NYSE:BIO) Q2 2019 Earnings Conference Call August 1, 2019 5:00 PM ET Company Participants Ronald Hutton - VP & Treasurer Ilan Daskal - EVP & CFO Norman Schwartz - Chairman, CEO & President Andrew Last - EVP & COO Annette Tumolo - EVP & President of Life Science Group John Hertia - EVP & President, Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Goldman Sachs Group Mitchell Petersen - Barclays Bank Daniel Leonard - Deutsche Bank Brandon Couillard - Jefferies O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...